What question did this study set out to answer?

This research aims to compare the biocompatibility and cellular uptake of donepezil-loaded nanoparticles and liposomes for Alzheimer's disease treatment.

May 20, 2026Open Access

Comparative evaluation of donepezil-loaded polymeric and liposomal nanoparticles for Alzheimer's disease: biocompatibility, drug release kinetics, and cellular uptake study

Key Points

This research aims to compare the biocompatibility and cellular uptake of donepezil-loaded nanoparticles and liposomes for Alzheimer's disease treatment.
Evaluated the dimensions and biocompatibility of donepezil-loaded PCL/PVA nanoparticles and DPPC liposomes.
Assessed cellular uptake of both forms of drug delivery at the nanoscale.
Polymeric nanoparticles showed significantly greater cellular uptake than liposomal counterparts.
Both formulations exhibited safe profiles with nanoscale dimensions.

Abstract

Donepezil-loaded PCL/PVA nanoparticles and DPPC liposomes exhibited nanoscale dimensions and a safe profile. Polymeric nanoparticles exhibited greater cellular uptake, highlighting the influence of nanocarrier composition on cell-nanoparticle interactions.

Comparative evaluation of donepezil-loaded polymeric and liposomal nanoparticles for Alzheimer's disease: biocompatibility, drug release kinetics, and cellular uptake study

Key Points

Abstract

Cite This Study

Also Consider

Also Consider